The University of Liverpool have pioneered the designs and synthesis of a new class of antibiotics. Our synthesis platform is robust, automated, and scalable and uses low-cost goods. Synthetic teixobactins kill resistant bacterial pathogens without detectable resistance and have the potential to provide new treatment options to save countless lives globally.
Take a look at the finalists across the four competition categories
Find out more